UBS Maintains Neutral Stance on Blue Owl Capital (OWL)
Finance

UBS Maintains Neutral Stance on Blue Owl Capital (OWL)

authorBy Strive Masiyiwa
DateJun 17, 2026
Read time3 min

UBS has reiterated its Neutral rating for Blue Owl Capital Inc. (NYSE:OWL), setting a price target of $9.50. Despite some potential upside, the firm's analysis indicates that the uncertainties surrounding private credit growth and business development companies make a significant reacceleration unlikely. UBS believes that overcoming these challenges to achieve a sustainable low-to-mid-teens fee-related earnings compound annual growth rate through 2028 will be difficult for the company.

UBS Keeps Neutral Outlook on Blue Owl Capital Amidst Market Uncertainties

On June 11, 2026, the financial services giant UBS confirmed its 'Neutral' rating for Blue Owl Capital Inc. (NYSE:OWL), a prominent alternative asset management firm. The bank established a price target of $9.50 per share. This decision comes after a thorough bull-bear assessment, which highlighted that while Blue Owl Capital might possess some inherent growth potential, significant upward movement is currently hampered by lingering uncertainties within the private credit sector and the performance of business development companies.

UBS's comprehensive analysis suggests that the stock is likely to trade within a confined range, as the prevailing 'bear points' currently outweigh the 'bull points'. The firm indicated that a more optimistic outlook on Blue Owl Capital would necessitate a clearer path to achieving a consistent low-to-mid-teens compound annual growth rate in fee-related earnings. This objective, according to UBS, presents a considerable challenge for the company to surmount in the period leading up to 2028.

Following a recent dip from its peak valuation, Blue Owl Capital's shares are presently trading at approximately 9.9 times UBS's projected distributable earnings per share for 2027, and 9.4 times broader market estimates. UBS observed a slight easing of pressure on OWL shares in recent weeks, accompanied by a modest, albeit low-conviction, increase in investor interest. Blue Owl Capital, a key player in alternative asset management, operates across three core business segments: credit, real assets, and GP Strategic Capital. The company specializes in delivering private capital solutions to businesses and offers distinctive alternative investment avenues to a diverse clientele, including institutional investors, individual wealth managers, and insurance companies.

From a journalist's perspective, UBS's reaffirmation of a neutral rating on Blue Owl Capital provides a valuable snapshot of the cautious sentiment pervading certain segments of the financial market. While Blue Owl Capital operates in the dynamic and often lucrative alternative asset management space, the report underscores the importance of sector-specific headwinds, particularly in private credit and business development. It highlights that even for established players, sustained growth requires overcoming formidable challenges and demonstrating consistent, robust financial performance. This analysis serves as a reminder that investment decisions, especially in complex financial instruments, should always be underpinned by a thorough understanding of both macro and microeconomic factors, urging investors to look beyond immediate upside and consider long-term viability and risk profiles.

More Articles
Finance
Uniswap's UNI Token Sees Significant Gains as Standard Chartered Predicts $100 by 2030
The UNI token, associated with the decentralized exchange Uniswap, has experienced a notable surge, reaching a one-month high. This rise follows a Standard Chartered research forecast predicting UNI to hit $100 by 2030, driven by its growing role in DeFi and recent innovations like tokenized securities. The token's performance also reflects increasing institutional interest and strategic upgrades within the Uniswap ecosystem.
By Nouriel RoubiniJun 17, 2026
Finance
Bunge Stock Rating Adjusted: From 'Buy' to 'Hold' Amidst Near Record Highs
Bunge's stock has surged over 45% since September 2025, approaching its 2008 peak of $135 per share. Despite this impressive rally, the risk/reward balance has shifted, prompting a downgrade from "Buy" to "Hold." While the long-term outlook remains positive due to strong agribusiness positioning, growing biofuel demand, and attractive valuation with a 2.39% dividend yield, potential market correction risks are increasing. Upcoming earnings and sustained high agricultural commodity prices could further boost profitability, but a more cautious stance is now warranted.
By Mariana MazzucatoJun 17, 2026
Finance
Navan: A Strong Near-Term Performer with Long-Term AI Risks
Navan has seen a significant post-IPO surge, doubling its value from year-to-date lows following a robust Q1 performance. Despite this recent upward trend, it remains below its initial public offering price of $25. The author reiterates a "Sell" rating, citing inherent industry challenges and the potential threat of artificial intelligence to Navan's future growth, especially when compared to other Software as a Service (SaaS) companies. Given its current enterprise value of $4.28 billion, Navan appears overvalued, facing considerable risks and uncertainties in its long-term growth trajectory.
By Michele FerreroJun 17, 2026
Finance
Amazon: A Giant Continuously Expanding Its Empire
Amazon maintains a 'Strong Buy' rating due to improving fundamentals, despite recent stock underperformance. Double-digit revenue growth across core sectors and a 28% year-over-year increase in AWS revenue demonstrate its robust and diverse business model. A 30% surge in operating cash flow fuels Amazon's ambitious AI and capital expenditure projects, including key collaborations with Nvidia and Anthropic. While challenges like slower growth and economic headwinds exist, the underlying bullish outlook remains strong.
By Strive MasiyiwaJun 17, 2026
Finance
Novo Nordisk: A Pharmaceutical Leader Navigating Competitive Pressures and Valuation
Novo Nordisk, a key player in GLP-1 therapies, faces intensified competition from Eli Lilly. The company's revenue heavily relies on semaglutide, with approximately 74% derived from this drug. Despite a significant stock decline, its valuation aligns with historical lows, reflecting market concerns about eroding competitive advantages. The current fair value, calculated through DCF analysis, suggests a "Hold" rating, indicating limited upside potential. Investors are advised to monitor market share dynamics, phase 3 trial results, and pipeline developments before considering increased exposure.
By Strive MasiyiwaJun 17, 2026